NCT03366766 2026-02-20
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 2 Terminated
Clinical Trials
151 trialsNCT04037527 2026-02-04
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Wake Forest University Health Sciences
Phase 1 Terminated
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT06199466 2025-12-08
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01495676 2025-10-10
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Terminated
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT03520790 2025-03-21
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02512692 2024-11-18
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
Medical University of South Carolina
Phase NA Terminated
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT02295722 2024-07-08
GEMHDM2014
AHS Cancer Control Alberta
Phase 1/2 Terminated
NCT05105412 2024-07-08
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
National Health Research Institutes, Taiwan
Phase 1/2 Terminated
NCT03450018 2024-05-24
SLC-0111-17-01
British Columbia Cancer Agency
Phase 1/2 Terminated
NCT04088188 2024-05-06
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Academic and Community Cancer Research United
Phase 1 Terminated
NCT04430036 2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT03519308 2024-03-15
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT04046887 2024-01-05
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Indiana University
Phase 1 Terminated
NCT00679029 2023-12-11
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Phase 2 Terminated
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT02887248 2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02383433 2023-10-23
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03714555 2023-10-18
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
HonorHealth Research Institute
Phase 2 Terminated
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT03662074 2023-08-02
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT04156828 2023-06-29
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
Phase 1 Terminated
NCT00323063 2023-03-29
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03524898 2022-09-28
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
Swiss Cancer Institute
Phase 1/2 Terminated
NCT00754364 2022-09-10
Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients
Istituto Clinico Humanitas
Phase 2 Terminated
NCT03422523 2022-08-22
ARGO
University Hospital Southampton NHS Foundation Trust
Phase 2 Terminated
NCT01573780 2022-08-15
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Terminated
NCT01525069 2022-08-10
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
Phase 1 Terminated
NCT00394147 2022-08-05
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT02414724 2022-07-25
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
Roswell Park Cancer Institute
Phase 1 Terminated
NCT03041181 2022-07-11
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02608229 2021-04-21
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Washington University School of Medicine
Phase 1 Terminated
NCT00438204 2021-04-13
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00470249 2021-02-01
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
University of Southampton
Phase 2 Terminated
NCT02992340 2021-01-14
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
ASLAN Pharmaceuticals
Phase 1/2 Terminated
NCT03468075 2020-12-10
Gemcitabine Plus Ascorbate for Sarcoma in Adults
University of Iowa
Phase 2 Terminated
NCT01938716 2020-11-05
Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00429858 2020-09-18
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03344172 2020-05-14
17-134
University of Pittsburgh
Phase 2 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT01431794 2020-01-22
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT02487277 2020-01-02
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
Phase 2 Terminated
NCT02589145 2019-12-13
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01240304 2019-12-10
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
University of Arkansas
Phase 2 Terminated